M&A activity last week saw BioCryst Pharmaceuticals announce it will acquire fellow USA-based Astria Therapeutics along with ...

Positive results have been presented on Datroway (datopotamab deruxtecan) from the TROPION-Breast02 Phase III trial at the ...

DESTINY-Breast05 Phase III trial data has shown that Enhertu (trastuzumab deruxtecan) led to a highly statistically ...

More positive data has been presented at the ESMO Congress on Enhertu (trastuzumab deruxtecan), a specifically engineered ...

Germany’s Merck KGaA has presented longer-term results from the global Phase III MANEUVER trial evaluating pimicotinib at the ...

Roche late Friday released results from two Phase III studies - dubbed MEERKAT and SANDCAT - evaluating the efficacy and ...

Isotope Technologies Munich (ITM) has announced a higher objective response rate (ORR) and prolonged median progression-free ...

New York-based Immunai, a biotech that uses single-cell genomics and machine learning to discover and improve development of ...

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has presented new data showing the impact of its PD-L1 inhibitor Imfinzi ...

Chinese biotech Kelun-Biotech (HKEX: 6990) has gained approval from the National Medical Products Administration for ...

US pharma major Eli Lilly has announced results from the primary overall survival (OS) analysis of the Phase III monarchE ...

The European Medicine Agency’s (EMA) human medicines committee (CHMP) recommended two novel medicines for approval at its ...